What’s new

• Board approved 1:10 stock split, subdividing ₹10 face value to Re 1.
• Three directors resigned, including executive director Vinod Mehta.
• Three new directors appointed; committees reconstituted.

Why it matters

For a ₹279-cr nano-cap with a P/E of 1233 and trailing revenue down 73.5%, a stock split is a liquidity move. But the simultaneous departure of an executive director and promoter reclassification add governance flux after last month's MD exit.

What we’re watching

• Shareholder and regulatory approvals for the split and record date.
• Whether the new directors bring stability after recent MD exit.
• Any impact on control from promoter reclassification to public status.

The full read

Integrated Proteins approved a 1:10 stock split. Each ₹10 share becomes ten Re 1. Goal: liquidity. But fundamentals are weak — trailing revenue down 73.5%, latest quarterly sales ₹6 cr, zero net profit, P/E 1233. Three directors resigned, including executive director Vinod Mehta. Immediate replacements appointed. Promoter reclassification okayed. Hardly a growth story. For a company with ₹0 cr net profit in the March quarter, the split is a liquidity tool, not a value signal. The board churn follows last month's MD exit. The new directors must show stability quickly.

Primary source: BSE · NSE

What’s new

• Board to meet July 3 to consider sub-division of equity shares.
• No other agenda items were disclosed.
• Split subject to shareholder and regulatory approvals.

Why it matters

For a nano-cap with negligible earnings power (trailing 12-month PAT near zero), a stock split is a cosmetic move. It does not change the underlying business or create value. The real story is the company's 73.5% revenue decline, not the par value.

What we’re watching

• Whether the split ratio and any rationale are disclosed after the board meeting.
• Shareholder approval timeline – splits require special resolution.
• Any concurrent disclosure of business plans or fundraising.

The full read

Integrated Proteins Ltd., a nano-cap trader with a market cap of ₹279 crores, will meet on July 3 to discuss a stock split. The company reported just ₹6 crores in sales and zero profit in the March quarter. Trailing revenue is down 73.5%. A split, if approved by shareholders and regulators, changes the number of shares but not the business. No new strategy, no turnaround plan, no capital infusion. The market's attention should be on how management intends to stem the decline, not on the par value.

Primary source: BSE · NSE

What’s new

• Karanj Doshi resigned as MD effective 29 June 2026, citing personal reasons.
• Company confirms no other material reasons; departure also ends his KMP role.
• No successor announced; board met in Jamnagar to approve resignation.

Why it matters

For a nano-cap trading at a P/E of 1,233 with revenue down 73.5% and net profit of nil in the latest quarter, losing the MD with zero notice is a governance red flag. The absence of a handover or succession plan raises questions about operational continuity and investor confidence.

What we’re watching

• Whether the board names a replacement before the July 3 stock split meeting.
• Any further KMP departures or governance changes.
• Impact on the already-planned stock split consideration.

The full read

Integrated Proteins is now without a managing director. Karanj Doshi resigned effective immediately on 29 June 2026, citing personal reasons. For a nano-cap with a ₹279 crore market cap, trailing revenues down 73.5%, and a latest quarterly net profit of ₹0, the abrupt departure of its top executive is a material blow. The company says there are no other reasons, but the resignation letter was tendered and accepted the same day—no handover, no successor named. The board met in Jamnagar to approve the exit. This leaves a leadership vacuum at a time when the business is already shrinking and the next board meeting, on July 3, is supposed to consider a stock split. Nano-caps lean heavily on key personnel; this one now has a governance gap with no timeline to fill it. The next board update will be watched closely for any succession plan.

Primary source: BSE · NSE

What’s new

• Revenue fell to ₹9.94 cr from ₹21.49 cr in FY2025.
• Net profit held steady at ₹0.23 cr, compared to ₹0.25 cr last year.
• The audit report is unmodified with no new strategic updates.

Why it matters

The results show a significant contraction in top-line performance for the ₹251 cr market-cap company. With no new orders or strategic shifts, the stagnant profit despite the revenue drop suggests a lack of growth momentum.

What we’re watching

• Any signs of revenue stabilization in the coming quarters.
• Volume trends for this nano-cap stock.
• Future disclosures regarding business expansion.

The full read

Integrated Proteins reported its audited results for FY2026, revealing a sharp decline in business activity. Revenue fell to ₹9.94 crore from ₹21.49 crore in the previous fiscal year.

Growth stalled.

Despite the 54% drop in top-line, the company managed to keep net profit nearly flat at ₹0.23 crore, compared to ₹0.25 crore in FY2025. The filing is routine, containing an unmodified audit opinion and standard compliance disclosures, with no new orders, strategic shifts, or unexpected items to report for a company with a market capitalization of ₹251 crore. These results offer little in the way of a new trading signal, confirming a period of contraction while the lack of forward-looking commentary leaves the outlook for the business entirely unchanged.

Primary source: BSE · NSE